2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate:Exports & Compliance White Paper 2026

I. Executive Summary

2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (CAS 125700-67-6), abbreviated TBTU, converts a carboxylic acid into an activated O-benzotriazolyl ester in situ, enabling amide bond formation with low racemisation. It is not a therapeutic agent and carries no approved indication: lots are either labelled Research Use Only (RUO) or supplied as a documented input to GMP peptide campaigns, so every commercial question is decided downstream at the peptide API plant. With a molar mass of 321.09 g/mol and decomposition above roughly 200 °C, it demands deliberate control of water activity and impurity signature.

Three forces shape demand. Expansion of therapeutic peptide manufacturing has turned coupling reagents into tonne-scale inputs, one large campaign consuming hundreds of kilograms per year. Solvent policy has become reagent policy: the DMF restriction under REACH Annex XVII entry 76, applicable since December 2023, pushes producers towards solvents where solubility and stability both differ. And the hazard profile of benzotriazole-derived species has driven partial migration to Oxyma-based reagents such as COMU, without yet displacing benzotriazolyl salts from validated filed processes.

The consequence is that the product can no longer be bought as a catalogue commodity. The uronium versus aminium solid-state form, residual tetramethylurea, chloride carry-over from metathesis and water activity now drive release timing and cost of goods. GMP lots must carry an impurity narrative aligned to ICH M7, Q3C and Q3D; RUO lots may legitimately carry a lighter package at lower unit cost. This paper maps the technology, regulatory perimeter, logistics and supplier ecosystems so buyers can qualify supply on evidence rather than headline assay.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The reagent belongs to the family of in-situ activating onium salts built on a benzotriazole leaving group. Three elements govern behaviour: the HOBt-derived leaving group, the tetramethylguanidinium core and the tetrafluoroborate counter-ion. Because dosing is by moles, appearance tells a buyer little - activity losses surface as deletion-sequence impurities that only costly preparative chromatography can purge.

• Uronium Versus Aminium Solid-State Form: Although sold as a uronium salt, crystallographic work on this class repeatedly shows N-linked aminium (guanidinium) isomers dominating the solid-state population and coexisting with the O-bonded form. Both converge on the same activated ester once carboxylate and base are present, so the issue is analytical: it shifts the DSC endotherm reported near 200 °C with concurrent decomposition and changes dissolution kinetics. Specifications should rest on assay, Karl Fischer water and clarity of solution, not a melting range that drifts with isomer ratio.
• Tetrafluoroborate Counter-Ion and Competing Guanylation: BF4- is chosen because it is non-nucleophilic and gives a far less hygroscopic product than the chloride obtained from the chloroformamidinium intermediate. Once carboxylate displaces benzotriazolyloxy, the OBt ester is the true acylating species; the competing pathway is attack of the amine on the uronium centre, capping the chain as a guanidinium adduct that survives to the crude peptide. Reagent excess, slow dissolution and poor base choice favour it, so modern protocols dose near stoichiometry with controlled addition order.

2.2 Synthesis and Manufacturing Technologies

Manufacture converges on two operations: building the tetramethyluronium core, then installing the benzotriazolyloxy moiety with anion exchange to tetrafluoroborate. Suppliers describe this at route-class level - the defensible intellectual property lies in crystallisation control, phlegmatisation and drying discipline, which determine residual chloride, particle habit and shelf life.

• Chloroformamidinium Activation with Anion Metathesis: The dominant route activates 1,1,3,3-tetramethylurea with phosgene, triphosgene or oxalyl chloride to give the N,N,N',N'-tetramethylchloroformamidinium chloride intermediate, condenses it with 1-hydroxybenzotriazole, then performs metathesis with tetrafluoroboric acid or an alkali tetrafluoroborate. It is economical but leaves residual chloride worth monitoring: it raises corrosivity in stainless equipment and accelerates hydrolytic loss of assay in storage.
• Phlegmatised Crystallisation, Drying and Particle Engineering: Because benzotriazole-derived intermediates can show self-reactive behaviour when dried to very low residual solvent or water activity, the critical unit operations are isolation and finishing. Producers keep the solid within a controlled moisture window, run rate-controlled crystallisation in jacketed vessels with calorimetric characterisation of the exotherm, and avoid micronising or long dry-blending that creates fines and hot spots.

2.3 Core Application Matrix

• Therapeutic Peptide API Manufacture (SPPS and Hybrid LPPS): The dominant outlet is chain assembly in solid-phase and hybrid liquid-phase campaigns - incretin analogues, calcitonins and GnRH analogues among them. Reagent is consumed stoichiometrically per residue, so consumption scales with chain length and tonnage, and assay drift means under-dosed couplings.
• Fragment Condensation and Macrocyclisation: Segment coupling of purified fragments and macrocyclisation under high dilution carry the highest consequence per kilogram. Low epimerisation is decisive at cysteine, histidine and serine, and addition sequences suppressing guanylation matter most here, since one failed coupling destroys accumulated intermediate value.
• CDMO Process Development and Internal Reference Standards: Contract manufacturers consume the reagent during route scouting, design-of-experiments optimisation and method development, and qualify an anchor lot as reference so incoming batches are benchmarked by head-to-head coupling before release.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand tracks peptide capacity almost one-for-one. Dedicated incretin capacity built in Europe, North America, India and China has created call-offs measured in tonnes. The shift towards hybrid and convergent liquid-phase routes aimed at cutting solvent intensity often increases discrete solution-phase couplings, raising rather than lowering specific consumption. Meanwhile alternative activation platforms - T3P-type phosphonic anhydride chemistry, catalytic amidation, Oxyma-derived salts - compete for the same process-chemistry budget.

3.2 Capacity Distribution and Export Flows

Production is concentrated but not monopolised. Mainland China hosts the largest base for benzotriazole derivatives, protected amino acids and coupling reagents across Zhejiang, Jiangsu and Shandong, mixing integrated producers with finishers converting imported intermediates. India's strength is downstream: peptide API clusters around Hyderabad, Bengaluru and Gujarat import most reagent. Europe and North America retain specialist documented production plus repacking into catalogue packs. Customs treatment under heading 2933 - reagent versus intermediate versus laboratory preparation - can delay clearance for weeks when paperwork is thin.

3.3 Market Bifurcation and Pricing Dynamics

The market is bifurcated. RUO material trades as a commodity priced off HOBt and tetramethylurea availability, boron trifluoride derivatives, energy and freight; documented GMP-supported material trades at a multiple of that, buying stability data, change control, drug master file referencing and audit responsiveness. The hidden lever is water: material assaying 99 % but carrying 0.8 % water delivers less active reagent per kilogram, silently producing incomplete couplings. Compare quotes on an active-substance basis with assay and water reported together.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

The reagent is not a drug substance and needs no marketing authorisation, yet it sits inside a regulated perimeter wherever it supports a clinical or commercial peptide process. Obligations split in two: those of the producer as a chemical manufacturer, and those of the buyer who must show that changes reach the filed process only with notice.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH Registration and Only-Representative Duty: Any party placing one tonne or more per year of CAS 125700-67-6 on the EU market must hold a registration, and with most capacity outside the Union the practical route is an only representative maintaining the IUCLID dossier. Typical tonnage falls in the first-tier information band, and joint submission through the existing consortium avoids duplicate studies. Verify status and tonnage coverage before tendering: a supplier whose representative withdraws leaves customers with an unlawful supply position.
• CLP Classification, HOBt Handling Conditions and the DMF Restriction: Classification and Labelling Inventory notifications in this class are usually self-classifications covering skin irritation, serious eye irritation and single-exposure target organ toxicity. Two adjacent matters matter more: HOBt must be kept under desensitised conditions, typically a defined water content, because dried material attracts reactivity screening governing storage and movement; and Annex XVII entry 76 restricts DMF from December 2023 unless exposure limits are met, reshaping the solvents in which this reagent is used. Residual tetramethylurea needs explicit limits under European reproductive-toxicity scrutiny.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA Inventory Status and Import Certification: US import requires the substance to appear on the TSCA Inventory as active, confirmed before the first consignment; absent or inactive status means a premanufacture notification or exemption, with lead time in months. Importers certify under inventory-hold-release rules, and denied-party screening applies to every shipment as standard practice for dual-usable fine chemicals even where the reagent is unscheduled.
• FDA-Driven Expectations: Type II DMF Support, ICH M7 and Q3D: For regulated campaigns a Type II API drug master file held by the producer or its agent is referenced in the applicant's NDA or ANDA; generic peptide programmes are most sensitive, since any route, specification or site change demands documented change control. Reviewers now ask for genotoxic impurity assessment under ICH M7, solvent control under Q3C and an elemental-impurity narrative under Q3D. Boron is not Q3D-listed, so boron residues are managed by ion chromatography or ICP.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Environmental pressure arrives indirectly, through the solvents and waste streams of peptide manufacture. European customers now cascade Scope 3 emissions questionnaires and supplier codes of conduct down to reagent suppliers, and producers unable to answer with quantified data lose tender access.

5.1 Carbon Footprint and Circular Economy

The dominant cradle-to-gate contributor is not the two-step synthesis but upstream solvent energy - DMF and acetonitrile production, distillation recovery, drying and nitrogen blanketing. Peptide processes carry process mass intensity values in the hundreds, and green-chemistry guidance has long targeted stoichiometric activation for replacement, so buyers should expect questions about how much footprint rides on the activation strategy. Tetrafluoroborate streams need deliberate handling: fluoride and boron species resist biodegradation, so boron liquors are consolidated for specialised treatment or high-temperature destruction rather than discharge.

5.2 Sustainable Sourcing and Traceability

Traceability now reaches back to the two problematic ancestors, HOBt and tetramethylurea; buyers want to know which plant made them and under what occupational controls. Third-party assessment is the common language - EcoVadis scorecards, Together for Sustainability audits and product carbon footprint reporting are routinely exchanged at qualification. End-use discipline is part of the same package: counterparty screening, end-use declarations confirming industrial or research application, and explicit RUO marking.

VI. Supply Chain Resilience and Export Logistics

Logistics are less about transport hazard than about defending analytical quality between the dryer and the customer's weighing room. Failure modes seen in practice are caked product after moisture ingress and cross-contamination from shared equipment.

6.1 Packaging Standards and Moisture/Contamination Control

• Multi-Layer Moisture Barrier with Inert Headspace: Standard construction is a heat-sealed aluminium-foil laminate bag with desiccant and nitrogen displacement inside a polyethylene liner and sealed drum. Brief exposure to ambient humidity can breach a tight water specification, so producers pack under controlled dew point immediately after drying rather than after bulk storage.
• UN-Certified Outer Packaging and Cleanliness Evidence: Outer packaging should be UN-certified to the appropriate performance level, typically combination packs of fibre or rigid plastic drums with liner. Because chloride residues are irritant and corrosive, packers avoid reactive bare metal contact, use dedicated or demonstrably cleaned filling lines, and supply cleaning records with certificates of conformance.

6.2 Dangerous Goods Identification and Transit Protocols

Many consignments in this class move as not-otherwise-regulated goods, but that is a claim requiring evidence: each producer must hold classification screening covering explosive and self-reactive behaviour before declaring exemption. Read Section 14 of the safety data sheet alongside those reports and treat discrepancies as substantive. Where a classification is triggered, IMDG, ADR and IATA rules govern packing group, marking and the shipper's declaration. Otherwise thermal management dominates: lots move under controlled ambient conditions, with refrigerated 2-8 °C transport reserved for high-value shipments, since dwelling above roughly 30 °C degrades assay. Bonded warehousing in Rotterdam, Singapore, Los Angeles and Mumbai lets plants hold safety stock without carrying full inventory cost.

VII. Enterprise Global Expansion Strategy Guide

Suppliers that win industrialise documentation rather than chase spot price. Buyers should structure qualification around the questions an auditor would ask a year later, since reagent qualification is expensive to repeat.

1. Operate a Two-Grade Qualification Architecture: Separate RUO catalog supply from documented GMP-supported supply commercially and qualitatively. RUO lots still carry identity, assay and water data but not change-control commitments; GMP-supported lots arrive under a quality agreement promising advance notice of route, site, specification or packaging changes, backed by a Type II DMF reference the buyer's submission can cite.
2. Qualify on Performance Attributes Rather Than Appearance: Require the datasets listed in Section 4.3, then qualify each source with a standardised model coupling - a reproducible acid-amine pair assayed by HPLC for conversion, guanylation adduct and epimerisation - against a retained reference lot. Days rather than months of work, and it catches what certificates miss: material assaying well yet delivering sluggish couplings.
3. De-Risk Through Dual Sourcing and Solvent Adaptability: Hold at least two qualified sources in different jurisdictions and clusters, because energy curtailment, environmental inspection and freight disruption routinely remove regional capacity for weeks. Require solubility, dissolution and stability data in non-amidic systems - acetonitrile blends, N-butylpyrrolidone, dimethyl carbonate - since solvent substitution is compliance-driven.

VIII. Conclusion

The outlook for CAS 125700-67-6 through 2026 is stable to growing volume with rising qualification barriers. Tonnage follows peptide capacity, still expanding across incretin and generic franchises, while substitution stays gradual because replacing an activation reagent in a validated process demands work few sponsors undertake without cause.

Advantage accrues to organisations treating the product as a controlled input rather than a catalogue item: buy on active-substance basis, demand the M7, Q3C and Q3D narrative, insist on evidenced transport classification and maintain dual sources across clusters. Sourcing hygiene - RUO labelling, end-use declarations and counterparty screening - keeps a legitimate research and industrial reagent chain defensible.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate supply chain:

• Mainland China (Zhejiang, Jiangsu and Shandong Reagents Belt): The volume centre of gravity, mixing integrated producers of tetramethylurea, HOBt and protected amino acids with finishers converting imported intermediates. Strengths are cost, rapid scale-up and adjacency to peptide consumables; scrutinise residual-solvent data, only-representative arrangements for Europe and water control at scale.
• India (Hyderabad, Bengaluru and Gujarat Peptide Corridor): Demand-led rather than reagent-led: peptide API and CDMO capacity absorbs large imported volumes and now nurtures domestic production for RUO distribution and import substitution. Participants are strongest on regulatory responsiveness and documentation built for ANDA-driven programmes.
• Europe and North America (German, Swiss and US Northeast Specialists): A lower-volume, higher-assurance tier supplying documented lots, small-pack repacking and bonded warehousing under mature quality systems. Premium pricing reflects change control and audit readiness; trade-offs are longer custom lead times and thin redundancy when one site is disrupted.